MedTrace Logo

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

NCT01214122 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-01-29

No results posted yet for this study

Summary

The primary purpose of this study is to determine whether the treatment with AZD9668 will affect the metabolism and effect of Warfarin.

Conditions

  • Pharmacokinetics
  • Pharmacodynamics

Interventions

DRUG

AZD9668

60 mg orally twice daily for 11 days

DRUG

Warfarin

10 x 2.5 (25) mg orally once daily on day 1 and on day 14

Sponsors & Collaborators

Principal Investigators

  • Christopher D O'Brien, MD, PhD · AstraZeneca R&D

  • Ingemar Bylesjö, MD · Berzelius Clinical Reseach Centre

  • Wolfgang Kühn, MD · Quintiles AB, Phase 1 Services

Study Design

Purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01214122 on ClinicalTrials.gov